Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial

Bulletin of the World Health Organization

Volumn 89, Issue 6, 2011, Pages 451-458

  Nacro, Boubacar ^a   Zoure, Emmanuelle ^a   Hien, Hervé ^b   Tamboura, Hassane ^a   Rouet, François ^b   Ouiminga, Adama ^b   Drabo, Ali ^b   Yameogo, Souleymane ^a   Hien, Alain ^a   Peyriere, Hélène ^c   Mathieu, Olivier ^c   Hirt, Deborah ^d   Treluyer, Jean Marc ^d   Nicolas, Joëlle ^c   Foulongne, Vincent ^e   Segondy, Michel ^e   van de Perre, Philippe ^e   Diagbouga, Serge ^b   Msellati, Philippe ^f  

^a Centre Hospitalier Universitaire Souro Sanou   (Burkina Faso)

^b CENTRE MURAZ   (Burkina Faso)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIV MONTPELLIER   (France)

^f Institut de Recherche pour le Developpement Cameroon   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; VIRUS RNA;

BIOCHEMISTRY; CHILD; DISEASE CONTROL; DISEASE TREATMENT; DRUG RESISTANCE; HEMATOLOGY; HOSPITAL SECTOR; HUMAN IMMUNODEFICIENCY VIRUS; MEDICINE;

AFRICA; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD MORTALITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION;

ADOLESCENT; AFRICA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; SURVIVAL ANALYSIS;

BURKINA FASO;

HUMAN IMMUNODEFICIENCY VIRUS 1; JOTURUS PICHARDI;

EID: 79958068158     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.10.081646     Document Type: Article

References (22)

1. AIDS epidemic update. Geneva: United Nations Joint Programme on HIV/AIDS; 2009.
2. Children and AIDS: fourth stocktaking report. New York: United Nations Children's Fund; 2009.
3. Rouet F, Fassinou P, Inwoley A, Anaky MF, Kouakoussui A, Rouzioux C et al. Long-term survival and immuno-virologic response of African HIV-1-infected children to highly active antiretroviral therapy regimens containing a protease or a non-nucleoside reverse transcriptase inhibitor. AIDS 2006;20:2315-2319. doi:10.1097/QAD.0b013e328010943b PMID:17117017
4. Eley B, Davies MA, Apolles P, Cowburn C, Buys H, Zampoli M et al. Antiretroviral treatment for children. S Afr Med J 2006;96:988-93. PMID:17077930
5. Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics 2007;120:e856-e861. doi:10.1542/peds.2006-1122 PMID:17846147
6. Ellis J, Molyneux EM. Experience of anti-retroviral treatment for HIV-infected children in Malawi: the 1st 12 months. Ann Trop Paediatr 2007;27:261-267. doi:10.1179/146532807X245643 PMID:18053342
7. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS 2008;22:245-251. doi:10.1089/apc.2007.0049 PMID:18298315
8. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA et al.; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-2244. doi:10.1056/NEJMoa0800971 PMID:19020325
9. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S et al.; Imea 011/ANRS 12-04 Study Group. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS 2003;17:1017-1022. doi:10.1097/00002030-200305020-00010 PMID:12700451
10. Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis 2003;36:1186-1190. doi:10.1086/374602 PMID:12715315
11. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Arici C et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther 2003;8:339-346. PMID:14518703
12. Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007;45:380-388. doi:10.1097/QAI.0b013e3180640cf5 PMID:17468666
13. Pasquier C, Millot N, Njouom R, Sandres K, Cazabat M, Puel J et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods 2001;94:45-54. doi:10.1016/S0166-0934(01)00272-5 PMID:11337039
14. Knupp CA, Stancato FA, Papp EA, Barbhaiya RH. Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography. J Chromatogr A 1990;533:282-290. doi:10.1016/S0378-4347(00)82215-X PMID:2127936
15. Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E et al. Didanosine population pharmacokinetics in West African HIV-infected children administered once daily tablets in relation to efficacy after one year of treatment. Antimicrob Agents Chemother 2009;53:4399-4406. doi:10.1128/AAC.01187-08 PMID:19581461
16. Harker AJ, Evans GL, Hawley AE, Morris DM. High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum. J Chromatogr B Biomed Appl 1994;657:227-232. doi:10.1016/0378-4347(94)80092-8 PMID:7952073
17. Cociglio M, Hillaire-Buys D, Peyrière H, Alric R. Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma. J Chromatogr Sci 2003;41:80-86. PMID:12639255
18. Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S et al. Is the recommended dose of efavirenz optimal in young West African HIV-infected children? Antimicrob Agents Chemother 2009;53:4407-4413. doi:10.1128/AAC.01594-08 PMID:19635964
19. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. Geneva: World Health Organization; 2006.
20. Smith K, Kuhn L, Coovadia A, Meyers T, Hu CC, Reitz C et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS 2009;23:1097-1107.doi:10.1097/QAD.0b013e32832afefc PMID:19417581
21. Chaix ML, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire. Pediatr Infect Dis J 2005;24:1072-1076. doi:10.1097/01.inf.0000190413.88671.92 PMID:16371868
22. L'Homme RF, Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008;22:557-565. doi:10.1097/QAD.0b013e3282f4a208 PMID:18316996